The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas

Mutations in the telomerase reverse transcriptase gene promoter (TERTp) are common in glioblastomas (GBMs) and oligodendrogliomas (ODGs), and therefore, have a key role in tumorigenesis and may be of prognostic value. However, the extent of their prognostic importance in various gliomas is controversial. We studied 168 patients separated into five groups: Group 1: 65 patients with ODG carrying an IDH1 or IDH2 mutation (IDH-mutant) and 1p/19q–codeletion, Group 2: 23 patients with anaplastic astrocytoma (AA), IDH-mutant, Group 3: 13 patients with GBM, IDH-mutant, Group 4: 15 patients with AA, IDH-wildtype (WT), and Group 5: 52 patients with GBM, IDH-WT. TERTp mutations were found in 96.9%, 4.4%, 76.9%, 20.0%, and 84.6% of patients in Groups 1, 2, 3, 4, and 5, respectively. The R132H mutation in IDH1 was found in 60.5% (23/38) of patients in the AA cohort (Groups 2 and 4) and 20.0% (13/65) of patients from our GBM cohort (Groups 3 and 5), whereas all patients with ODG (Group 1) had a mutation either in IDH1 (n = 62) or IDH2 (n = 3). Using Kaplan Meier survival analysis, we found that the TERTp mutation was correlated with poor overall survival (OS) in Groups 2 and 4 combined (P = 0.001) and in Group 4 (P = 0.113), and in multivariate analysis, the TERTp mutant group was associated with significantly poor survival in Group 5 (P = 0.045). However, IDH mutation, MGMT methylation, and younger patient age (<55 years old) were significantly correlated with favorable OS (all P < 0.05) in our cohort of astrocytic and ODGs. In patients with ODG (Group 1), mutant IDH and TERTp did not have prognostic value because these mutations were universally present. Based on the revised 2016 WHO classification of gliomas, we found that TERTp mutation was frequently present in patients with GBM or ODG and because it was strongly correlated with poor survival outcome in patients with IDH-WT GBM in multivariate analysis, it may be of prognostic value in this subgroup of patients with gliomas.

[1]  H Duffau,et al.  Temozolomide for low-grade gliomas , 2007, Neurology.

[2]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[3]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[4]  K. Hoang-Xuan,et al.  TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations , 2014, British Journal of Cancer.

[5]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Pieter Wesseling,et al.  Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. , 2016, Neuro-oncology.

[7]  Jian Zhu,et al.  Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. , 2011, Medical hypotheses.

[8]  R. Reddel,et al.  Alternative lengthening of telomeres: models, mechanisms and implications , 2010, Nature Reviews Genetics.

[9]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[10]  L. Kang,et al.  RTEL1 and TERT polymorphisms are associated with astrocytoma risk in the Chinese Han population , 2013, Tumor Biology.

[11]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[12]  G. Gao,et al.  Selected polymorphisms of GSTP1 and TERT were associated with glioma risk in Han Chinese. , 2012, Cancer epidemiology.

[13]  Jennie W. Taylor,et al.  Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT , 2017, Acta Neuropathologica.

[14]  A. Gu,et al.  The TERT MNS16A polymorphism contributes to cancer susceptibility: meta-analysis of the current studies. , 2013, Gene.

[15]  D. Gomez,et al.  AZT as a telomerase inhibitor , 2012, Front. Oncol..

[16]  K. McMartin,et al.  Formate assay in body fluids: application in methanol poisoning. , 1975, Biochemical medicine.

[17]  M. Stenmark-Askmalm,et al.  TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma , 2015, Oncotarget.

[18]  A. Auvinen,et al.  MNS16A minisatellite genotypes in relation to risk of glioma and meningioma and to glioblastoma outcome , 2009, International journal of cancer.

[19]  P. Kleihues,et al.  TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.

[20]  Darell D. Bigner,et al.  Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas , 2014, Oncotarget.

[21]  A. von Deimling,et al.  Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma , 2013, Cell cycle.

[22]  J. Boyle,et al.  Cancer-associated TERT promoter mutations abrogate telomerase silencing , 2015, eLife.

[23]  Zhifeng Shi,et al.  Adult IDH wild-type lower-grade gliomas should be further stratified , 2017, Neuro-oncology.

[24]  Hai Yan,et al.  Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. , 2011, Current opinion in neurology.

[25]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[26]  K. Ichimura,et al.  Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss , 2013, Acta Neuropathologica.

[27]  M. Ruden,et al.  Novel anticancer therapeutics targeting telomerase. , 2013, Cancer treatment reviews.